{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:54:17Z","timestamp":1784638457036,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Typhoidal <jats:italic>Salmonella<\/jats:italic> is a major global problem affecting more than 12 million people annually. Controlled human infection models (CHIMs) in high-resource settings have had an important role in accelerating the development of conjugate vaccines against <jats:italic>Salmonella<\/jats:italic> Typhi.<\/jats:p><jats:p>The typhoidal <jats:italic>Salmonella<\/jats:italic> model has an established safety profile in over 2000 volunteers in high-income settings, and trial protocols, with modification, could be readily transferred to new study sites. To date, a typhoidal <jats:italic>Salmonella<\/jats:italic> CHIM has not been conducted in a low-resource setting, although it is being considered.<\/jats:p><jats:p>Our article describes the challenges posed by a typhoidal <jats:italic>Salmonella<\/jats:italic> CHIM in the high-resource setting of Oxford and explores considerations for an endemic setting.<\/jats:p><jats:p>Development of CHIMs in endemic settings is scientifically justifiable as it remains unclear whether findings from challenge studies performed in high-resource non-endemic settings can be extrapolated to endemic settings, where the burden of invasive <jats:italic>Salmonella<\/jats:italic> is highest. Volunteers are likely to differ across a range of important variables such as previous <jats:italic>Salmonella<\/jats:italic> exposure, diet, intestinal microbiota, and genetic profile. CHIMs in endemic settings arguably are ethically justifiable as affected communities are more likely to gain benefit from the study. Local training and research capacity may be bolstered.<\/jats:p><jats:p>Safety was of primary importance in the Oxford model. Risk of harm to the individual was mitigated by careful inclusion and exclusion criteria; close monitoring with online diary and daily visits; 24\/7 on-call staffing; and access to appropriate hospital facilities with capacity for in-patient admission. Risk of harm to the community was mitigated by exclusion of participants with contact with vulnerable persons; stringent hygiene and sanitation precautions; and demonstration of clearance of <jats:italic>Salmonella<\/jats:italic> infection from stool following antibiotic treatment.<\/jats:p><jats:p>Safety measures should be more stringent in settings where health systems, transport networks, and sanitation are less robust.<\/jats:p><jats:p>We compare the following issues between high- and low-resource settings: scientific justification, risk of harm to the individual and community, benefits to the individual and community, participant understanding, compensation, and regulatory requirements.<\/jats:p><jats:p>We conclude that, with careful consideration of country-specific ethical and practical issues, a typhoidal <jats:italic>Salmonella<\/jats:italic> CHIM in an endemic setting is possible.<\/jats:p>","DOI":"10.1186\/s13063-019-3844-z","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:03:46Z","timestamp":1576713826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Typhoidal Salmonella human challenge studies: ethical and practical challenges and considerations for low-resource settings"],"prefix":"10.1186","volume":"20","author":[{"given":"Meriel","family":"Raymond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malick M.","family":"Gibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P. J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phaik Yeong","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"issue":"9753","key":"3844_CR1","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","volume":"376","author":"AM Dondorp","year":"2010","unstructured":"Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647\u201357.","journal-title":"Lancet."},{"issue":"7","key":"3844_CR2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","volume":"15","author":"TC Darton","year":"2015","unstructured":"Darton TC, Blohmke CJ, Moorthy VS, Altmann DM, Hayden FG, Clutterbuck EA, et al. Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infect Dis. 2015;15(7):840\u201351.","journal-title":"Lancet Infect Dis"},{"key":"3844_CR3","volume-title":"Sixty-seventh report","author":"World Health Organization Expert Committee on Biological Standardization","year":"2017","unstructured":"World Health Organization Expert Committee on Biological Standardization. Annex 10 Human challenge trials for vaccine development: regulatory considerations. In: Sixty-seventh report; 2017. http:\/\/apps.who.int\/medicinedocs\/documents\/s23329en\/s23329en.pdf. Accessed 28 Sept 2018."},{"issue":"10","key":"3844_CR4","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S1473-3099(18)30177-4","volume":"18","author":"M Roestenberg","year":"2018","unstructured":"Roestenberg M, Hoogerwerf MA, Ferreira DM, Mordmuller B, Yazdanbakhsh M. Experimental infection of human volunteers. Lancet Infect Dis. 2018;18(10):e312\u2013e22.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"3844_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/08998280.2005.11928028","volume":"18","author":"S Riedel","year":"2005","unstructured":"Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18(1):21\u20135.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"2","key":"3844_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pt.2016.11.001","volume":"33","author":"RO Payne","year":"2017","unstructured":"Payne RO, Griffin PM, McCarthy JS, Draper SJ. Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. Trends Parasitol. 2017;33(2):141\u201350.","journal-title":"Trends Parasitol"},{"issue":"5","key":"3844_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4269\/ajtmh.2009.09-0194","volume":"81","author":"S Herrera","year":"2009","unstructured":"Herrera S, Fernandez O, Manzano MR, Murrain B, Vergara J, Blanco P, et al. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg. 2009;81(5):740\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"3844_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12936-015-0671-x","volume":"14","author":"SH Hodgson","year":"2015","unstructured":"Hodgson SH, Juma E, Salim A, Magiri C, Njenga D, Molyneux S, et al. Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya. Malar J. 2015;14:182.","journal-title":"Malar J"},{"issue":"3","key":"3844_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","volume":"91","author":"S Shekalaghe","year":"2014","unstructured":"Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91(3):471\u201380.","journal-title":"Am J Trop Med Hyg."},{"issue":"49","key":"3844_CR10","doi-asserted-by":"publisher","first-page":"7040","DOI":"10.1016\/j.vaccine.2012.09.061","volume":"30","author":"L Bodhidatta","year":"2012","unstructured":"Bodhidatta L, Pitisuttithum P, Chamnanchanant S, Chang KT, Islam D, Bussaratid V, et al. Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine. 2012;30(49):7040\u20135.","journal-title":"Vaccine."},{"issue":"4","key":"3844_CR11","first-page":"263","volume":"3","author":"MJ Selgelid","year":"2018","unstructured":"Selgelid MJ, Jamrozik E. Ethical challenges posed by human infection challenge studies in endemic settings. Indian J Med Ethics. 2018;3(4):263\u20136.","journal-title":"Indian J Med Ethics"},{"key":"3844_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.12688\/wellcomeopenres.12256.1","volume":"2","author":"SB Gordon","year":"2017","unstructured":"Gordon SB, Rylance J, Luck A, Jambo K, Ferreira DM, Manda-Taylor L, et al. A framework for Controlled Human Infection Model (CHIM) studies in Malawi: Report of a Wellcome Trust workshop on CHIM in Low Income Countries held in Blantyre, Malawi. Wellcome Open Res. 2017;2:70.","journal-title":"Wellcome Open Res"},{"key":"3844_CR13","unstructured":"Palacious RSS. The case of Zika virus controlled human infection model studies. Trials. 2018."},{"issue":"Suppl 4","key":"3844_CR14","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1093\/cid\/civ673","volume":"61","author":"MM Gibani","year":"2015","unstructured":"Gibani MM, Jin C, Darton TC, Pollard AJ. Control of Invasive Salmonella Disease in Africa: Is There a Role for Human Challenge Models? Clin Infect Dis. 2015;61(Suppl 4):S266\u201371.","journal-title":"Clin Infect Dis"},{"key":"3844_CR15","volume-title":"Guidelines on clinical evaluation of vaccines: regulatory expectations","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. 2016. http:\/\/www.who.int\/biologicals\/BS2287_Clinical_guidelines_final_LINE_NOs_20_July_2016.pdf. Accessed 1 Oct 2018."},{"key":"3844_CR16","volume-title":"Controlled Human Infection Model Studies","author":"The Academy of Medical Sciences","year":"2018","unstructured":"The Academy of Medical Sciences. Controlled Human Infection Model Studies. 2018. https:\/\/www.hic-vac.org\/sites\/default\/files\/Controlled%20Human%20Infection%20Model%20Studies%20AMS%20report%202018.pdf. Accessed 27 Sept 2018."},{"issue":"10","key":"3844_CR17","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","volume":"2","author":"V Mogasale","year":"2014","unstructured":"Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2(10):e570\u201380.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"3844_CR18","doi-asserted-by":"publisher","first-page":"e0005376","DOI":"10.1371\/journal.pntd.0005376","volume":"11","author":"M Antillon","year":"2017","unstructured":"Antillon M, Warren JL, Crawford FW, Weinberger DM, Kurum E, Pak GD, et al. The burden of typhoid fever in low- and middle-income countries: A meta-regression approach. PLoS Negl Trop Dis. 2017;11(2):e0005376.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"3844_CR19","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2214-109X(17)30022-0","volume":"5","author":"F Marks","year":"2017","unstructured":"Marks F, von Kalckreuth V, Aaby P, Adu-Sarkodie Y, El Tayeb MA, Ali M, et al. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health. 2017;5(3):e310\u2013e23.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"3844_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1353\/dem.2005.0002","volume":"42","author":"D Cutler","year":"2005","unstructured":"Cutler D, Miller G. The role of public health improvements in health advances: the twentieth-century United States. Demography. 2005;42(1):1\u201322.","journal-title":"Demography."},{"issue":"3","key":"3844_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"key":"3844_CR22","doi-asserted-by":"publisher","unstructured":"Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins. MBio. 2018;9(1):e00105\u201318. https:\/\/doi.org\/10.1128\/mBio.00105-18. PMID: 29463654; PMCID: PMC5821095.","DOI":"10.1128\/mBio.00105-18"},{"issue":"14","key":"3844_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJM197010012831406","volume":"283","author":"RB Hornick","year":"1970","unstructured":"Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med. 1970;283(14):739\u201346.","journal-title":"N Engl J Med"},{"issue":"5","key":"3844_CR24","first-page":"405","volume":"68","author":"CS Waddington","year":"2014","unstructured":"Waddington CS, Darton TC, Woodward WE, Angus B, Levine MM, Pollard AJ. Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies. J Inf Secur. 2014;68(5):405\u201318.","journal-title":"J Inf Secur"},{"issue":"10111","key":"3844_CR25","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","volume":"390","author":"C Jin","year":"2017","unstructured":"Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390(10111):2472\u201380.","journal-title":"Lancet."},{"issue":"2","key":"3844_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","volume":"37","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Typhoid Vaccines: WHO Position Paper \u2013 March 2018. Vaccine. 2018. https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.022.","journal-title":"Vaccine"},{"key":"3844_CR27","volume-title":"Typbar TCV\u00ae from Bharat Biotech, World\u2019s First Typhoid Conjugate Vaccine Prequalified by WHO","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Typbar TCV\u00ae from Bharat Biotech, World\u2019s First Typhoid Conjugate Vaccine Prequalified by WHO. 2018."},{"issue":"Supplement_2","key":"3844_CR28","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1093\/cid\/ciy1103","volume":"68","author":"JE Meiring","year":"2019","unstructured":"Meiring JE, Laurens MB, Patel P, Patel P, Misiri T, Simiyu K, et al. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi. Clin Infect Dis. 2019;68(Supplement_2):S50\u2013S8.","journal-title":"Clin Infect Dis"},{"issue":"Supplement_2","key":"3844_CR29","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1093\/cid\/ciy1106","volume":"68","author":"K Theiss-Nyland","year":"2019","unstructured":"Theiss-Nyland K, Shakya M, Colin-Jones R, Voysey M, Smith N, Karkey A, et al. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial. Clin Infect Dis. 2019;68(Supplement_2):S67\u201373.","journal-title":"Clin Infect Dis"},{"issue":"Supplement_2","key":"3844_CR30","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1093\/cid\/ciy1107","volume":"68","author":"K Theiss-Nyland","year":"2019","unstructured":"Theiss-Nyland K, Qadri F, Colin-Jones R, Zaman K, Khanam F, Liu X, et al. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial. Clin Infect Dis. 2019;68(Supplement_2):S74\u201382.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3844_CR31","doi-asserted-by":"publisher","first-page":"e007481","DOI":"10.1136\/bmjopen-2014-007481","volume":"5","author":"D McCullagh","year":"2015","unstructured":"McCullagh D, Dobinson HC, Darton T, Campbell D, Jones C, Snape M, et al. Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers. BMJ Open. 2015;5(6):e007481.","journal-title":"BMJ Open"},{"issue":"8","key":"3844_CR32","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/cid\/cix042","volume":"64","author":"HC Dobinson","year":"2017","unstructured":"Dobinson HC, Gibani MM, Jones C, Thomaides-Brears HB, Voysey M, Darton TC, et al. Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. Clin Infect Dis. 2017;64(8):1066\u201373.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3844_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/jme.2003.004440","volume":"30","author":"T Hope","year":"2004","unstructured":"Hope T, McMillan J. Challenge studies of human volunteers: ethical issues. J Med Ethics. 2004;30(1):110\u20136.","journal-title":"J Med Ethics"},{"key":"3844_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-2334-14-73","volume":"14","author":"CM Parry","year":"2014","unstructured":"Parry CM, Thompson C, Vinh H, Chinh NT, Phuong le T, Ho VA, et al. Risk factors for the development of severe typhoid fever in Vietnam. BMC Infect Dis. 2014;14:73.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"3844_CR35","first-page":"197","volume":"65","author":"S Balasegaram","year":"2012","unstructured":"Balasegaram S, Potter AL, Grynszpan D, Barlow S, Behrens RH, Lighton L, et al. Guidelines for the public health management of typhoid and paratyphoid in England: practice guidelines from the National Typhoid and Paratyphoid Reference Group. J Inf Secur. 2012;65(3):197\u2013213.","journal-title":"J Inf Secur"},{"issue":"1","key":"3844_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1556264618820219","volume":"14","author":"SA Kraft","year":"2019","unstructured":"Kraft SA, Duenas DM, Kublin JG, Shipman KJ, Murphy SC, Shah SK. Exploring Ethical Concerns About Human Challenge Studies: A Qualitative Study of Controlled Human Malaria Infection Study Participants\u2019 Motivations and Attitudes. J Empir Res Hum Res Ethics. 2019;14(1):49\u201360.","journal-title":"J Empir Res Hum Res Ethics"},{"key":"3844_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.12688\/wellcomeopenres.14439.2","volume":"3","author":"M Njue","year":"2018","unstructured":"Njue M, Njuguna P, Kapulu MC, Sanga G, Bejon P, Marsh V, et al. Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. Wellcome Open Res. 2018;3:39.","journal-title":"Wellcome Open Res"},{"issue":"1","key":"3844_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/phe\/phv026","volume":"9","author":"B Bambery","year":"2016","unstructured":"Bambery B, Selgelid M, Weijer C, Savulescu J, Pollard AJ. Ethical Criteria for Human Challenge Studies in Infectious Diseases. Public Health Ethics. 2016;9(1):92\u2013103.","journal-title":"Public Health Ethics"},{"issue":"1","key":"3844_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12936-017-1718-y","volume":"16","author":"K Sahan","year":"2017","unstructured":"Sahan K, Pell C, Smithuis F, Phyo AK, Maung SM, Indrasuta C, et al. Community engagement and the social context of targeted malaria treatment: a qualitative study in Kayin (Karen) State, Myanmar. Malar J. 2017;16(1):75.","journal-title":"Malar J"},{"issue":"7","key":"3844_CR40","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1086\/322664","volume":"33","author":"FG Miller","year":"2001","unstructured":"Miller FG, Grady C. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis. 2001;33(7):1028\u201333.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3844_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/jme.2007.021857","volume":"34","author":"A Wertheimer","year":"2008","unstructured":"Wertheimer A, Miller FG. Payment for research participation: a coercive offer? J Med Ethics. 2008;34(5):389\u201392.","journal-title":"J Med Ethics"},{"issue":"8","key":"3844_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMsb1710591","volume":"378","author":"L Gelinas","year":"2018","unstructured":"Gelinas L, Largent EA, Cohen IG, Kornetsky S, Bierer BE, Fernandez LH. A Framework for Ethical Payment to Research Participants. N Engl J Med. 2018;378(8):766\u201371.","journal-title":"N Engl J Med"},{"issue":"2","key":"3844_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.inhe.2010.02.001","volume":"2","author":"PY Cheah","year":"2010","unstructured":"Cheah PY, Lwin KM, Phaiphun L, Maelankiri L, Parker M, Day NP, et al. Community engagement on the Thai-Burmese border: rationale, experience and lessons learnt. Int Health. 2010;2(2):123\u20139.","journal-title":"Int Health"},{"issue":"7475","key":"3844_CR44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/bmj.329.7475.1114","volume":"329","author":"Z Bhutta","year":"2004","unstructured":"Bhutta Z. Standards of care in research. BMJ. 2004;329(7475):1114\u20135.","journal-title":"BMJ."},{"issue":"5","key":"3844_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411\u201323.","journal-title":"N Engl J Med"},{"key":"3844_CR46","unstructured":"European Medicines Agency International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice guidelines. 1996. ICH Topic E 6 (R1) Guideline for Good Clinical Practic. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e6-r1-guideline-good-clinical-practice_en.pdf. Accessed 19 Nov 2019."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3844-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3844-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3844-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:47:34Z","timestamp":1608252454000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3844-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":46,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3844"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3844-z","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"19 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"704"}}